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HIV-1 diversity and the 
implementation of integrase 
strand-transfer inhibitors as part of 
combination antiretroviral therapy
To the Editor: The integrase (IN) strand-transfer inhibitor (InSTI) 
dolutegravir (DTG) is now recommended by the World Health 
Organization as part of salvage and/or first-line combination 
antiretroviral therapy (cART).[1] DTG has a high genetic barrier 
against developing resistance and is effective against all strains 
that previously exhibited resistance-associated mutations (RAMs) 
against other cART regimens.[2] Recommendations to use DTG were 
delayed owing to preliminary findings from Botswana that indicated 
potential safety concerns in pregnancy, with a small increased risk of 
neural tube defects.[3] Studies that investigated the safety and efficacy 
of DTG now support its use in all populations, including pregnant 
women and those of childbearing potential.[4,5]
HIV-1 genetic diversity continues to make it difficult to control 
the pandemic. New subtypes are still being identified, with HIV-1 
subtype L only being described and characterised in 2019.[6] It is well 
known that HIV-1 diversity remains a key challenge pertaining to 
a wide spectrum of fields, such as serological diagnoses, virological 
follow-up, vaccine development and therapeutic monitoring. 
Although HIV-1 subtype C is prevalent in southern Africa, the 
majority of the HIV-1 groups and subtypes, including circulating 
recombinant forms (CRFs), can be found in Africa. [7] Some 
mutation pathways clearly differ by subtype variation. For example, 
a study by Doyle et al.[8] comparing major IN RAMs in raltegravir 
(RAL) recipients at positions 148 and 140 of IN between subtype 
B and non-B clades found that these mutations were exclusively 
present in subtype B sequences. The G118R InSTI mutation was 
only found among individuals infected with HIV-1 subtype C and 
CRF02_AG. This mutation is rarely present in HIV-1 subtype B.[9] 
It has been postulated that G118R could be an alternative pathway 
for DTG resistance in non-subtype B viruses, whereas R263K is the 
preferred pathway for subtype B viruses.[10] Of note, the majority of 
group O viruses are naturally resistant to non-nucleoside reverse 
transcriptase inhibitors owing to the presence of the C181Y 
mutation in the reverse transcriptase gene.[9] In our studies, we 
observed low-level RAMs against InSTIs.[7,11,12] The effect of these 
mutations is yet to be fully understood. Through our structural 
modelling and docking studies, we observed differences of InSTIs 
drug-binding interactions to different HIV-1 IN subtypes, but 
we did not observe any significant differences in binding affinity 
for each InSTI.[13-15] This finding implies no significant alteration 
to the binding site in the wild-type IN, which may consequently 
prevent InSTI drug binding. By using triple therapy, the impact of 
developing clinical resistance should be limited if patients remain 
fully adherent. In cases where it is suspected that cART failure is 
due to resistance development, resistance testing should be done 
before patients are switched to a new regimen. We do support the 
full-scale use of DTG in African settings where diverse subtypes 
are prevalent. Continued close monitoring strategies to ensure 
a successful switch of regimens is warranted in patients with 
virological failure and who have developed resistance to their cART 
regimens.
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